In Segment A, individuals will get various doses and schedules of oral ABBV-744 tablet to establish Protected dosing routine. More participants are going to be enrolled on the determined monotherapy dosign program. In Phase B, contributors will receive oral ruxolitinib and ABBV-744 is going to be specified as "add-on" therapy. https://franky333qdo6.pennywiki.com/user